Literature DB >> 9333329

[Effect of hydroxyethyl starch solution on kidney function in surgical intensive care patients].

M G Dehne1, J Mühling, A Sablotzki, G Papke, U Kuntzsch, G Hempelmann.   

Abstract

Hydroxyethyl starch is commonly used in resuscitation, anaesthesia and intensive care medicine. Increasing creatinine values in patients treated with hydroxyethyl starch have been described in some case reports. These have also been some clinical signs such as pain in the renal region, and swelling of kidney parenchyma, but no differential and sensitive parameters of renal function have supported these possible side effects of hydroxyethyl starch. Twenty-five patients were randomly allocated to a control and a treatment group. In the treatment group, patients received 12 ml per kg body-weight hydroxyethyl starch 10% (200/0.5) daily. A non-invasive diagnostic spectrum of renal function was performed. Specific tubular proteins (alpha 1-microglobulin, Tamm-Horsfall protein), glomerular parameters (immunoglobulin G, albumin), and the brush border enzyme acetyl-beta-glucosaminidase, were examined. Additionally, renal blood flow and glomerular filtration rate, Apache-II-score, breathing therapy, infusions, transfusion, and all medical interventions were documented. Both groups were comparable with regard to drug therapy. Apache-II-score, and fluid management. There were differences in tubular function between the two groups. Patients undergoing HES therapy showed increased excretion of alpha 1-microglobulin. Tamm-Horsfall-protein and of brush border enzyme acetyl-beta-glucosaminidase. No significant differences were detectable in glomerular functions (glomerular filtration rate, renal blood flow), albumin, and IgG. Correlates of tubular damage after hydroxyethyl starch therapy were seen in intensive care patients. Many influences of intensive therapy act on renal function, and further studies with larger cohorts are necessary. With regard to the documented localisation of the tubular damage in the HES group, colloid therapy with hydroxyethyl starch in renal dysfunction should be monitored carefully by means of sensitive markers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333329     DOI: 10.1055/s-2007-995067

Source DB:  PubMed          Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther        ISSN: 0939-2661            Impact factor:   0.698


  5 in total

1.  Renal impairment in cardiac surgery patients receiving hydroxyethyl starch.

Authors:  Christian J Wiedermann
Journal:  Intensive Care Med       Date:  2004-01-16       Impact factor: 17.440

Review 2.  Are renal adverse effects of hydroxyethyl starches merely a consequence of their incorrect use?

Authors:  Christiane S Hartog; Frank M Brunkhorst; Christoph Engel; Andreas Meier-Hellmann; Maximilian Ragaller; Tobias Welte; Evelyn Kuhnt; Konrad Reinhart
Journal:  Wien Klin Wochenschr       Date:  2011-03-01       Impact factor: 1.704

3.  Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials: ATTENTION: The analysis and conclusions of this article are being revised by the authors. This is due to the journal Anesthesia and Analgesia's retraction of a paper by Dr. Joachim Boldt, an author in seven of the studies analyzed in this review. As such, the editors of Open Medicine recommend interpreting this review with extreme caution until Zarychanski et al. publish a new analysis and interpretation in Open Medicine. For more information, see Anesthesia and Analgesia's press release.

Authors:  Ryan Zarychanski; Alexis F Turgeon; Dean A Fergusson; Deborah J Cook; Paul Hébert; Sean M Bagshaw; Danny Monsour; Lauralyn McIntyre
Journal:  Open Med       Date:  2009-10-27

Review 4.  [Hydroxyethylstarch (HES)].

Authors:  Joachim Boldt
Journal:  Wien Klin Wochenschr       Date:  2004-03-31       Impact factor: 2.275

5.  Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials.

Authors:  Christian J Wiedermann; Stefan Dunzendorfer; Luigi U Gaioni; Francesco Zaraca; Michael Joannidis
Journal:  Crit Care       Date:  2010-10-28       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.